更新于：2024-06-29

Dopamine hydrochloride

盐酸多巴胺

更新于：2024-06-29

概要

概要

基本信息

简介Dopamine hydrochloride是多巴胺的盐酸盐形式，多巴胺是一种具有正性肌力作用的单胺化合物。Dopamine hydrochloride是一种多巴胺激动剂，可用于治疗心力衰竭和休克。该药物可通过激活多巴胺能受体，增加心脏收缩力和心输出量，提高血压和心脏功能。它可用于治疗由于心肌收缩力减弱或血容量不足引起的休克。多巴胺盐酸盐由Hospira公司开发并于1974年2月25日获得美国批准。

药物类型

小分子化药

别名

Dopamine hydrochloride (JP17/USP)、Neoatricon、ASL-279

+ [8]

靶点

DRDs

作用机制

DRDs激动剂(多巴胺受体家族激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Hospira, Inc.BrePco Biopharma Ltd.Tsuruhara Pharmaceutical Co. Ltd.

+ [2]

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (1974-02-25),

心脏衰竭

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看首次获批时间轴

结构

分子式C8H12ClNO2

InChIKeyCTENFNNZBMHDDG-UHFFFAOYSA-N

CAS号62-31-7

关联

项与盐酸多巴胺相关的临床试验

NCT06447740 / RecruitingN/AIIT

Fractional Flow Reserve-guided Percutaneous Renal Artery Stenting Plus Optimal Medical Therapy Versus Optimal Medical Therapy Alone In Atherosclerosis Renal-vascular Hypertension Patients: a Multicenter Randomized Trial

Although randomized trials have demonstrated there is no benefit of renal-artery stenting in addition to medical therapy for patients with atherosclerosis renal artery stenosis, many patients indeed gained benefit in daily practices after stenting, such as reduction in blood pressure and recovery in renal functions. One important gap is that there is no universal standard to determine whether to stent in these patients. Fraction Flow Reserve (FFR) has been studied for many year in chronic coronary heart disease and FFR-guided revascularization strategy is known to be better than both angiography-guided revascularization and medication alone. Based on the primary finding of FAIR-pilot study (NCT05732077), FFR-guided renal artery stenting is practical.
The overall purpose of the FAIR trial is to compare the clinical outcomes and safety of FFR-guided stenting plus optimal medical treatment (OMT) versus OMT alone in patients with renal-vascular hypertensive patients.
With the 'all comers' design, participants met the inclusive/exclusive criteria will be enrolled, and hyperemic FFR induced by dopamine will be measured in all participants. If FFR is ≥0.80, patients will be treated with OMT alone and follow up. If FFR is <0.80, participants will be randomized to stenting in the renal artery plus OMT or OMT alone on a 1:1 ratio. The blood pressure and anti-hypertensive medications will be compared before and 3 months after the procedure based on ambulatory blood pressure monitoring, all participants will be followed up for 1 year.

开始日期2024-06-03

申办/合作机构

北京大学第一医院

CTRI/2023/05/052798 / Not yet recruitingN/A

A Randomized control trial to determine effect of dopamine as vegf (Vascular endothelial growth factor) antagonist on development of acute lung injury in sepsis.

开始日期2023-05-26

申办/合作机构-

CTRI/2023/03/050166 / Not yet recruitingN/A

Dopamine Vs Epinephrine In Management Of Fluid Refractory Septic Shock In Neonates

开始日期2023-03-06

申办/合作机构-

100 项与盐酸多巴胺相关的临床结果

登录后查看更多信息

100 项与盐酸多巴胺相关的转化医学

登录后查看更多信息

100 项与盐酸多巴胺相关的专利（医药）

登录后查看更多信息

30,143

项与盐酸多巴胺相关的文献（医药）

2024-06-01·Bioelectrochemistry (Amsterdam, Netherlands)

Sensitive and selective electrochemical aptasensing method for the voltammetric determination of dopamine based on AuNPs/PEDOT-ERGO nanocomposites

Article

作者: Zhang, Dongdong ; Chen, Jiatao ; Li, Dandan ; Ding, Xiuting

In this study, the effects of phosphate buffered saline (PBS) and graphene oxide (GO) as supporting electrolytes and dopants on the electropolymerization process of 3,4-ethylenedioxythiophene (EDOT) on glassy carbon electrode (GCE) were investigated. It was found that the PEDOT-ERGO nanocomposites obtained by a simple one-step electrochemical redox polymerization method using GO as the only supporting electrolyte and dopant possess excellent electrochemical properties. Then, the PEDOT-ERGO nanocomposites were used as electrode substrate to further modify with AuNPs, and an electrochemical aptasensor based on AuNPs/PEDOT-ERGO nanocomposites was successfully constructed for the sensitive and selective determination of dopamine (DA). Comparison of the cyclic voltammetric response of different neurotransmitters before and after aptamer assembly showed that the aptamer significantly improved the selectivity of the sensor for DA. The low detection limit of 1.0 μM (S/N = 3) indicated the good electrochemical performance of the PEDOT-ERGO nanocomposite film. Moreover, the aptasensor showed good recoveries in 50-fold diluted fetal bovine serum with RSD values all less than 5 % (n = 5), indicating that the PEDOT-ERGO nanocomposites and the electrochemical aptasensor have promising applications in other neurochemicals assay and biomedical analysis.

2024-05-01·Current neuropharmacology

Surgical Advances in Parkinson’s Disease

Review

作者: Pavese, Nicola ; Hvingelby, Victor S.

Abstract::

While symptomatic pharmacological therapy remains the main therapeutic strategy for Parkinson’s disease (PD), over the last two decades, surgical approaches have become more commonly used to control levodopa-induced motor complications and dopamine-resistant and non-motor symptoms of PD. In this paper, we discuss old and new surgical treatments for PD and the many technological innovations in this field. We have initially reviewed the relevant surgical anatomy as well as the pathological signaling considered to be the underlying cause of specific symptoms of PD. Subsequently, early attempts at surgical symptom control will be briefly reviewed. As the most well-known surgical intervention for PD is deep brain stimulation, this subject is discussed at length. As deciding on whether a patient stands to benefit from DBS can be quite difficult, the different proposed paradigms for precisely this are covered. Following this, the evidence regarding different targets, especially the subthalamic nucleus and internal globus pallidus, is reviewed as well as the evidence for newer proposed targets for specific symptoms. Due to the rapidly expanding nature of knowledge and technological capabilities, some of these new and potential future capabilities are given consideration in terms of their current and future use. Following this, we have reviewed newer treatment modalities, especially magnetic resonance-guided focused ultrasound and other potential surgical therapies, such as spinal cord stimulation for gait symptoms and others. As mentioned, the field of surgical alleviation of symptoms of PD is undergoing a rapid expansion, and this review provides a general overview of the current status and future directions in the field.

2024-05-01·Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

Correction: Voltage-gated potassium channels control extended access cocaine seeking: a role for nucleus accumbens astrocytes

作者: Keohane, Shannon B ; Anderson, Tanner L ; Prantzalos, Emily R ; Turner, Jill R ; Ortinski, Pavel I ; Hawkinson, Tara R ; Sun, Ramon C ; Clarke, Harrison A ; Xia, Mengfan

Dopaminergic signaling in the nucleus accumbens shell (NAc) regulates neuronal activity relevant to reward-related learning, including cocaine-associated behaviors.Although astrocytes respond to dopamine and cocaine with structural changes, the impact of dopamine and cocaine on astrocyte functional plasticity has not been widely studied.Specifically, behavioral implications of voltage-gated channel activity in the canonically non-excitable astrocytes are not known.We characterized potassium channel function in NAc astrocytes following exposure to exogenous dopamine or cocaine self-administration training under short (2 h/day) and extended (6 h/day) access schedules.Electrophysiol., Ca²⁺ imaging, mRNA, and mass spectrometry tools were used for mol. characterization.Behavioral effects were examined after NAc-targeted microinjections of channel antagonists and astroglial toxins.Exogenous dopamine increased activity of currents mediated by voltage-gated (K_v7) channels in NAc astrocytes.This was associated with a ∼5-fold increase in expression of Kcnq2 transcript level in homogenized NAc micropunches.Matrix-assisted laser desorption/ionization mass spectrometry revealed increased NAc dopamine levels in extended access, relative to short access, rats.K_v7 inhibition selectively increased frequency and amplitude of astrocyte intracellular Ca²⁺ transients in NAc of extended access rats.Inhibition of K_v7 channels in the NAc attenuated cocaine-seeking in extended access rats only, an effect that was occluded by microinjection of the astrocyte metabolic poison, fluorocitrate.These results suggest that voltage-gated K⁺ channel signaling in NAc astrocytes is behaviorally relevant, support K_v7-mediated regulation of astrocyte Ca²⁺ signals, and propose novel mechanisms of neuroglial interactions relevant to drug use.

178

项与盐酸多巴胺相关的新闻（医药）

2024-06-17

·信狐药迅

仿制药申请5个品规发通知件；临床申请品种均默示许可| 新获批（6.11-6.16）

每周药品注册获批数据，分门别类呈现，一目了然。(6.11-6.16）新药上市申请药品名称企业注册分类受理号泽美洛韦玛佐瑞韦单抗注射液兴盟生物医药(苏州)有限公司1CXSS2200053国;CXSS2200053泽美洛韦玛佐瑞韦单抗注射液兴盟生物医药(苏州)有限公司1CXSS2200052国;CXSS2200052特瑞普利单抗注射液上海君实生物医药科技股份有限公司2.2CXSS2300053特瑞普利单抗注射液上海君实生物医药科技股份有限公司2.2CXSS2300052 新药临床申请药品名称企业注册分类受理号SK-08片康臣药业(内蒙古)有限责任公司1CXHL2400317SK-08片康臣药业(内蒙古)有限责任公司1CXHL2400316SK-08片康臣药业(内蒙古)有限责任公司1CXHL2400315YK-051南京优科制药有限公司1CXHL2400296HSK42360片西藏海思科制药有限公司1CXHL2400306HSK42360片西藏海思科制药有限公司1CXHL2400305ASP3082注射液安斯泰来(中国)投资有限公司1CXHL2400308HY-021068片合肥医工医药股份有限公司1CXHL2400330KY386注射用浓溶液深圳开悦生命科技有限公司1CXHL2400338ASKC200搽剂江苏奥赛康药业有限公司2.2CXHL2400321ASKC200搽剂江苏奥赛康药业有限公司2.2CXHL2400320布洛芬注射液山东新华制药股份有限公司3CYHL2400067布洛芬注射液山东新华制药股份有限公司3CYHL2400066注射用IAP0971盛禾(中国)生物制药有限公司1CXSL2400100注射用BGB-R046广州百济神州生物制药有限公司1CXSL2400208HY1272注射液恒翼生物医药(上海)股份有限公司1CXSL2400211 仿制药申请药品名称企业注册分类受理号帕拉米韦氯化钠注射液江苏吴中医药集团有限公司苏州制药厂3CYHS2202034国;CYHS2202034缩宫素注射液上海葆隆生物科技有限公司3CYHS2000879国;CYHS2000879尼莫地平口服溶液广东金城金素制药有限公司3CYHS2100073国;CYHS2100073艾司奥美拉唑镁肠溶胶囊浙江永太药业有限公司3CYHS2200943国;CYHS2200943艾司奥美拉唑镁肠溶胶囊浙江永太药业有限公司3CYHS2200941国;CYHS2200941氨甲环酸注射液烟台鲁银药业有限公司3CYHS2201532国;CYHS2201532氨甲环酸注射液烟台鲁银药业有限公司3CYHS2201531国;CYHS2201531己酮可可碱注射液湖南科伦制药有限公司3CYHS2201638国;CYHS2201638西洛他唑片成都倍特药业股份有限公司3CYHS2201667国;CYHS2201667己酮可可碱注射液苏州朗科生物技术股份有限公司3CYHS2201692国;CYHS2201692倍他米松磷酸钠注射液重庆华邦制药有限公司3CYHS2201703国;CYHS2201703帕拉米韦注射液福安药业集团烟台只楚药业有限公司3CYHS2201738国;CYHS2201738盐酸多巴胺注射液通合生物医药(山东)有限公司3CYHS2201817国;CYHS2201817重酒石酸间羟胺注射液海南天盛保和生物科技有限公司3CYHS2202126国;CYHS2202126盐酸多巴酚丁胺注射液北京布霖生物科技有限公司3CYHS2300097盐酸多巴酚丁胺注射液华夏生生药业(北京)有限公司3CYHS2300094盐酸肾上腺素注射液海南倍特药业有限公司3CYHS2300192法莫替丁注射液重庆药谷制药有限公司3CYHS2300234盐酸倍他司汀片森淼(山东)药业有限公司3CYHS2300349盐酸右美托咪定注射液山西远扬医药科技有限公司3CYHS2300625复方磷酸盐颗粒嘉实(湖南)医药科技有限公司3CYHS2301310中性腹膜透析液(碳酸氢盐-G4.25)芜湖道润药业有限责任公司3CYHS2201647国;CYHS2201647中性腹膜透析液(碳酸氢盐-G2.5)芜湖道润药业有限责任公司3CYHS2201646国;CYHS2201646中性腹膜透析液(碳酸氢盐-G1.5)芜湖道润药业有限责任公司3CYHS2201644国;CYHS2201644中性低钙腹膜透析液(碳酸氢盐-G2.5)芜湖道润药业有限责任公司3CYHS2201642国;CYHS2201642盐酸利多卡因局部溶液成都慧德医药科技有限公司3CYHS2301936恩曲他滨丙酚替诺福韦片石家庄龙泽制药股份有限公司4CYHS2202116国;CYHS2202116氨氯地平阿托伐他汀钙片昆山龙灯瑞迪制药有限公司4CYHS2300338低钙腹膜透析液(乳酸盐-G4.25)上海长征富民金山制药有限公司4CYHS2300883低钙腹膜透析液(乳酸盐-G2.5)上海长征富民金山制药有限公司4CYHS2300882低钙腹膜透析液(乳酸盐-G1.5)上海长征富民金山制药有限公司4CYHS2300881沙库巴曲缬沙坦钠片南京正大天晴制药有限公司4CYHS2101755国;CYHS2101755沙库巴曲缬沙坦钠片南京正大天晴制药有限公司4CYHS2101754国;CYHS2101754沙库巴曲缬沙坦钠片南京正大天晴制药有限公司4CYHS2101753国;CYHS2101753塞来昔布胶囊北京世桥生物制药有限公司4CYHS2200718国;CYHS2200718钆特醇注射液正大天晴药业集团股份有限公司4CYHS2200913国;CYHS2200913富马酸伏诺拉生片重庆华森制药股份有限公司4CYHS2200908国;CYHS2200908富马酸伏诺拉生片重庆华森制药股份有限公司4CYHS2200907国;CYHS2200907富马酸丙酚替诺福韦片南京海辰药业股份有限公司4CYHS2201237国;CYHS2201237地诺孕素片西安太极药业有限公司4CYHS2201323国;CYHS2201323溴芬酸钠滴眼液中山万汉制药有限公司4CYHS2201340国;CYHS2201340盐酸雷洛昔芬片重庆圣华曦药业股份有限公司4CYHS2201439国;CYHS2201439溴芬酸钠滴眼液中山万汉制药有限公司4CYHS2201616国;CYHS2201616左卡尼汀注射液华中药业股份有限公司4CYHS2201640国;CYHS2201640左卡尼汀注射液华中药业股份有限公司4CYHS2201639国;CYHS2201639缬沙坦氨氯地平片(I)长春海悦药业股份有限公司4CYHS2201717国;CYHS2201717注射用哌拉西林钠他唑巴坦钠江苏睿实生物科技有限公司4CYHS2201726国;CYHS2201726注射用哌拉西林钠他唑巴坦钠江苏睿实生物科技有限公司4CYHS2201725国;CYHS2201725盐酸乌拉地尔注射液吉林省辉南长龙生化药业股份有限公司4CYHS2201822国;CYHS2201822盐酸乌拉地尔注射液吉林省辉南长龙生化药业股份有限公司4CYHS2201821国;CYHS2201821奥拉帕利片杭州中美华东制药有限公司4CYHS2201855国;CYHS2201855奥拉帕利片杭州中美华东制药有限公司4CYHS2201854国;CYHS2201854溴莫尼定噻吗洛尔滴眼液艾尔健康眼药(辽宁)有限公司4CYHS2201864国;CYHS2201864丙酸氟替卡松雾化吸入用混悬液上海新黄河制药有限公司4CYHS2201885国;CYHS2201885枸橼酸西地那非口腔崩解片南京长澳制药有限公司4CYHS2201886国;CYHS2201886盐酸莫西沙星滴眼液海南斯达制药有限公司4CYHS2201904国;CYHS2201904伏立康唑片武汉启瑞药业有限公司4CYHS2201916国;CYHS2201916伏立康唑片武汉启瑞药业有限公司4CYHS2201915国;CYHS2201915富马酸丙酚替诺福韦片江苏科本药业有限公司4CYHS2201936国;CYHS2201936氢溴酸伏硫西汀片山东京卫制药有限公司4CYHS2202031国;CYHS2202031盐酸乌拉地尔注射液湖南科伦制药有限公司4CYHS2202064国;CYHS2202064盐酸乌拉地尔注射液湖南科伦制药有限公司4CYHS2202065国;CYHS2202065棕榈酸帕利哌酮注射液绿叶嘉奥制药石家庄有限公司4CYHS2202111国;CYHS2202111棕榈酸帕利哌酮注射液绿叶嘉奥制药石家庄有限公司4CYHS2202110国;CYHS2202110棕榈酸帕利哌酮注射液绿叶嘉奥制药石家庄有限公司4CYHS2202109国;CYHS2202109棕榈酸帕利哌酮注射液绿叶嘉奥制药石家庄有限公司4CYHS2202108国;CYHS2202108棕榈酸帕利哌酮注射液绿叶嘉奥制药石家庄有限公司4CYHS2202107国;CYHS2202107舒更葡糖钠注射液南京正大天晴制药有限公司4CYHS2202129国;CYHS2202129舒更葡糖钠注射液南京正大天晴制药有限公司4CYHS2202128国;CYHS2202128卡培他滨片江苏诚康药业有限公司4CYHS2202139国;CYHS2202139钆特酸葡胺注射液山东威智百科药业有限公司4CYHS2202160国;CYHS2202160钆特酸葡胺注射液山东威智百科药业有限公司4CYHS2202159国;CYHS2202159钆特酸葡胺注射液山东威智百科药业有限公司4CYHS2202158国;CYHS2202158注射用盐酸表柔比星浙江华海药业股份有限公司4CYHS2202149国;CYHS2202149马昔腾坦片上海旭东海普药业有限公司4CYHS2202176国;CYHS2202176碳酸镧咀嚼片江西施美药业股份有限公司4CYHS2300102左氧氟沙星滴眼液苏州弘森药业股份有限公司4CYHS2300098磷酸特地唑胺片桂林南药股份有限公司4CYHS2300180盐酸奥洛他定滴眼液国药集团三益药业(芜湖)有限公司4CYHS2300255他达拉非片新乡市常乐制药有限责任公司4CYHS2300274间苯三酚注射液湖南科伦制药有限公司4CYHS2300283富马酸比索洛尔片浙江京新药业股份有限公司4CYHS2300376富马酸比索洛尔片浙江京新药业股份有限公司4CYHS2300375沙美特罗替卡松吸入粉雾剂健康元药业集团股份有限公司4CYHS2300405注射用哌拉西林钠他唑巴坦钠成都倍特药业股份有限公司4CYHS2300450注射用哌拉西林钠他唑巴坦钠成都倍特药业股份有限公司4CYHS2300449注射用哌拉西林钠他唑巴坦钠成都倍特药业股份有限公司4CYHS2300448吸入用硫酸沙丁胺醇溶液浙江百代医药科技有限公司4CYHS2300508恩格列净片宁波大红鹰药业股份有限公司4CYHS2300601注射用头孢他啶阿维巴坦钠山东百诺医药股份有限公司4CYHS2300703阿卡波糖片成都恒瑞制药有限公司4CYHS2300702多巴丝肼片北京福元医药股份有限公司4CYHS2300742格列齐特缓释片浙江京新药业股份有限公司4CYHS2301097阿伐替尼片基石药业(苏州)有限公司4CYHS2301700奥美沙坦酯氨氯地平片郑州韩都药业集团有限公司4CYHS2301875氧九龙气体河北有限公司4CYHS2302089氧辉县市广福贸易有限公司4CYHS2302128氧香格里拉藏龙纯净氧气体有限公司4CYHS2302226盐酸特比萘芬乳膏齐鲁制药(海南)有限公司4CYHS2301721头孢托仑匹酯颗粒海南葫芦娃药业集团股份有限公司4CYHS2401101头孢托仑匹酯颗粒海南葫芦娃药业集团股份有限公司4CYHS2401100西甲硅油乳剂成都诺和晟鸿生物制药有限公司4CYHS2401170富马酸喹硫平片Dr. Reddy's Laboratories Ltd.5.2JYHS2101007国;JYHS2101007富马酸喹硫平片Dr. Reddy's Laboratories Ltd.5.2JYHS2101006国;JYHS2101006富马酸喹硫平片Dr. Reddy's Laboratories Ltd.5.2JYHS2101005国;JYHS2101005 进口申请药品名称企业注册分类受理号高血糖素鼻用粉雾剂Eli Lilly and Company5.1JXHS2200063国;JXHS2200063依伏卡塞片Kyowa Kirin Co., Ltd.5.1JXHS2200069国;JXHS2200069依伏卡塞片Kyowa Kirin Co., Ltd.5.1JXHS2200068国;JXHS2200068地舒单抗注射液Amgen Europe B.V.3.1JXSS2300031Balcinrenone达格列净胶囊AstraZeneca AB1JXHL2400070Balcinrenone达格列净胶囊AstraZeneca AB1JXHL2400069Golcadomide胶囊Celgene Corporation1JXHL2400084Golcadomide胶囊Celgene Corporation1JXHL2400083Golcadomide胶囊Celgene Corporation1JXHL2400082PF-07264660注射液Pfizer Inc.1JXSL2400066PF-07275315注射液Pfizer Inc.1JXSL2400065CID-103注射液CASI Pharmaceuticals, Inc.1JXSL2400067 中药相关申请无注：橙色字体部分结论为不批准或收到通知件；

申请上市临床申请

2024-06-12

·奇点网

细胞移植疗法向前进一步！

*仅供医学专业人士阅读参考帕金森病（PD）的特征性运动症状的直接原因是中脑多巴胺神经元不可逆地丢失，因此，干细胞移植被认为是一种很有潜力的PD治疗方法，已经在临床前和早期临床研究中进行了测试。然而，干细胞移植的体内细胞存活问题阻碍了这一疗法的应用。无论是自体、异体还是异种模式，胚胎和人多能干细胞衍生的多巴胺神经元在移植后，超90%都无法存活，较低的和不确定的细胞存活率（通常为0.5-10%）不仅会影响临床试验的结果，还会让研究人员无法确定合适剂量，大量移植以补偿有限存活可能会因为大量细胞死亡引起炎症反应。移植的多巴胺神经元为什么会大量死亡？搞不清楚这个问题，干细胞移植PD就难以正式投入临床。在今天的《细胞》上，斯隆·凯特琳癌症研究所的研究团队发表最新研究成果，他们发现，p53介导的细胞凋亡是多巴胺神经元死亡的主要原因，并且，肿瘤坏死因子α（TNF-α）-核因子κB（NF-κB）是诱导这一过程的上游信号通路，使用TNF-α抑制剂阿达木单抗可以提高PD小鼠模型中移植的多巴胺神经元存活率，且形成了广泛的神经再支配和功能恢复[1]。为了确定限制人多能干细胞来源的多巴胺神经元存活的内在因素，研究人员进行了CRISPR-Cas9筛选，他们使用了纯化的有丝分裂后多巴胺神经元，以专注于细胞存活，排除细胞增殖等混杂因素。在他们的实验中，多巴胺神经元的存活率为3%，确实存在存活率低的问题。初步筛选找到了9个限制体内多巴胺神经元存活的基因，并且强调了细胞凋亡和炎症是关键途径。进一步的验证实验显示p53是最强的影响因素，敲除p53能够显著改善多巴胺神经元的存活率，移植1个月后，从平均每10万细胞中存活2776±393增加至13667±2599，不仅如此，存活的多巴胺神经元中，黑质（A9）多巴胺神经元的比例增加，黑质多巴胺神经元尤其脆弱，在PD的发展中有更广泛更快速的丢失，但它对运动功能非常重要。从时间流程上来看，在移植后24小时，p53就会触发一个持续几天的细胞凋亡程序，72小时时细胞凋亡达到峰值，7天时，一波死亡基本完全结束。细胞凋亡的时间流程移植手术会引起血管系统局部损伤，血脑屏障暂时性受损，诱导受体的免疫反应。研究人员发现，移植物中的中性粒细胞和内皮细胞比例极低，表明外周血白细胞向注射部位的迁移很少，移植24小时后，小胶质细胞和星形胶质细胞极化并向着移植物迁移，这表明，它们是赶去处理已经开始批量死亡的移植细胞，而非通过免疫炎症驱动了移植细胞的死亡。众所周知，p53是肿瘤抑制因子，针对它进行干预难以进行临床转化，而且从机制上了解移植后24小时p53触发细胞凋亡过程的上游通路也是很重要的。研究人员为此进行了大量的神经元RNA测序，最后确定了富集程度最高的通路包括凋亡、p53和TNF-α。时间过程分析显示，近80%的移植细胞中，TNF-α下游的NF-κB在移植后4和24小时表现出强激活反应，在72小时后显著减少。体外的TNF-α直接诱导实验证实了NF-κB和p53的激活。NF-κB激活的时间过程 TNF-α抑制剂阿达木单抗是一种在临床上广泛使用的自身免疫疾病治疗药物，在我国已经获批用于治疗类风湿关节炎和强直性脊柱炎。体外实验显示，阿达木单抗显著提高了纯化的有丝分裂后多巴胺神经元在1个月时的存活率。研究人员觉得，阿达木单抗辅助治疗说不定能挽救PD的细胞移植。于是，他们选择了存在旋转行为的PD运动症状小鼠模型，随机分组接受磷酸缓冲液（PBS）、多巴胺神经元或多巴胺神经元+阿达木单抗联合治疗。在移植后6个月，多巴胺神经元和多巴胺神经元+阿达木单抗联合治疗组的运动症状均显著改善，但联合治疗组表现出更早、功能恢复更完整的趋势。联合治疗组的多巴胺神经元数量和总体积显著增加，黑质多巴胺神经元的比例更高，突触密度和纹状体中等多棘神经元（纹状体的主要投射神经元，细胞膜上表达不同类型的多巴胺受体）占比也更高。C：PBS（灰）、多巴胺神经元（黄）或多巴胺神经元+阿达木单抗联合治疗（蓝）的结果D：阿达木单抗辅助治疗后的多巴胺神经元数量和总体积增加综上，这项研究确定了细胞移植治疗PD时，移植后多巴胺神经元死亡的关键调控因子，以及潜在的解决方法。研究人员指出，探索同样的方法是否适用于其他中枢神经系统内外的细胞治疗是很有意义的，因为许多基于人多能干细胞的细胞治疗都存在有限的体内存活问题，是阻止治疗成功的主要障碍。参考文献：[1] https://www-cell-com.libproxy1.nus.edu.sg/cell/abstract/S0092-8674(24)00575-0本文作者丨应雨妍

细胞疗法基因疗法免疫疗法

2024-06-12

·Science Daily

Towards a new era in flexible piezoelectric sensors for both humans and robots

Flexible piezoelectric sensors are essential to monitor the motions of both humans and humanoid robots. However, existing designs are either are costly or have limited sensitivity. In a recent study, researchers tackled these issues by developing a novel piezoelectric composite material made from electrospun polyvinylidene fluoride nanofibers combined with dopamine. Sensors made from this material showed significant performance and stability improvements at a low cost, promising advancements in medicine, healthcare, and robotics. Flexible piezoelectric sensors are essential to monitor the motions of both humans and humanoid robots. However, existing designs are either are costly or have limited sensitivity. In a recent study, researchers from Japan tackled these issues by developing a novel piezoelectric composite material made from electrospun polyvinylidene fluoride nanofibers combined with dopamine. Sensors made from this material showed significant performance and stability improvements at a low cost, promising advancements in medicine, healthcare, and robotics. The world is accelerating rapidly towards the intelligent era -- a stage in history marked by increased automation and interconnectivity by leveraging technologies such as artificial intelligence and robotics. As a sometimes-overlooked foundational requirement in this transformation, sensors represent an essential interface between humans, machines, and their environment. However, now that robots are becoming more agile and wearable electronics are no longer confined to science fiction, traditional silicon-based sensors won't make the cut in many applications. Thus, flexible sensors, which provide better comfort and higher versatility, have become a very active area of study. Piezoelectric sensors are particularly important in this regard, as they can convert mechanical stress and stretching into an electrical signal. Despite numerous promising approaches, there remains a lack of environmentally sustainable methods for mass-producing flexible, high-performance piezoelectric sensors at a low cost. Against this backdrop, a research team from Shinshu University, Japan, decided to step up to the challenge and improve flexible piezoelectric sensor design using a well-established manufacturing technique: electrospinning. Their latest study, which was led by Distinguished Professor Ick Soo Kim in association with Junpeng Xiong, Ling Wang, Mayakrishnan Gopiraman, and Jian Shi, was published on 2 May, 2024, in the journal Nature Communications. The proposed flexible sensor design involves the stepwise electrospinning of a composite 2D nanofiber membrane. First, polyvinylidene fluoride (PVDF) nanofibers with diameters in the order of 200 nm are spun, forming a strong uniform network that acts as the base for the piezoelectric sensor. Then, ultrafine PVDF nanofibers with diameters smaller than 35 nm are spun onto the preexisting base. These fibers become automatically interweaved between the gaps of the base network, creating a particular 2D topology. After characterization via experiments, simulations, and theoretical analyses, the researchers found that the resulting composite PVDF network had enhanced beta crystal orientation. By enhancing this polar phase, which is responsible for the piezoelectric effect observed in PVDF materials, the piezoelectric performance of the sensors was significantly improved. To increase the stability of the material further, the researchers introduced dopamine (DA) during the electrospinning process, which created a protective core-shell structure. "Sensor fabricated from using PVDF/DA composite membranes exhibited superb performance, including a wide response range of 1.5-40 N, high sensitivity of 7.29 V/N to weak forces in the range of 0-4 N, and excellent operational durability," remarks Kim. These exceptional qualities were demonstrated practically using wearable sensors to measure a wide variety of human movements and actions. More specifically, the proposed sensors, when worn by a human, could produce an easily distinguishable voltage response to natural motions and physiological signals. This included finger tapping, knee and elbow bending, foot stamping, and even speaking and wrist pulses. Given the potential low-cost mass production of these piezoelectric sensors, combined with their use of environmentally friendly organic materials instead of harmful inorganics, this study could have important technological implications not only for health monitoring and diagnostics, but also robotics. "Despite the current challenges, humanoid robots are poised to play an increasingly integral role in the very near future. For instance, the well-known Tesla robot 'Optimus' can already mimic human motions and walk like a human," muses Kim, "Considering high-tech sensors are currently being used to monitor robot motions, our proposed nanofiber-based superior piezoelectric sensors hold much potential not only for monitoring human movements, but also in the field of humanoid robotics." To make the adoption of these sensors easier, the research team will be focusing on improving the material's electrical output properties so that flexible electronic components can be driven without the need for an external power source. Hopefully, further progress in this area will accelerate our stride towards the intelligent era, leading to more comfortable and sustainable lives.

100 项与盐酸多巴胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00633	-	C01CA04	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
低血压	欧盟	BrePco Biopharma Ltd.	2024-05-27
低血压	冰岛	BrePco Biopharma Ltd.	2024-05-27
低血压	列支敦士登	BrePco Biopharma Ltd.	2024-05-27
低血压	挪威	BrePco Biopharma Ltd.	2024-05-27
心源性休克	日本	Tsuruhara Pharmaceutical Co. Ltd.	1987-10-01
出血性休克	日本	Tsuruhara Pharmaceutical Co. Ltd.	1987-10-01
休克	美国	Hospira, Inc.	1981-05-19
心脏衰竭	美国	Hospira, Inc.	1974-02-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASN2022	N/A	急性肾损伤	-	Dopamine infusion	範觸鏇鑰繭鹽顧衊鑰衊(衊糧選艱觸壓選齋壓遞) = 餘鹽網範鑰繭顧艱醖襯襯壓淵鏇網襯繭蓋齋選 (製糧廠蓋簾鏇鬱簾鹽廠 )	-	2022-11-05
				No dopamine infusion	範觸鏇鑰繭鹽顧衊鑰衊(衊糧選艱觸壓選齋壓遞) = 簾衊壓鏇醖願廠鹹鏇壓襯壓淵鏇網襯繭蓋齋選 (製糧廠蓋簾鏇鬱簾鹽廠 )
ARVO2022	N/A	糖尿病性视网膜病变	-	Dopamine treatment	鑰顧遞鹽鑰餘積鏇糧簾(繭繭構餘構繭蓋遞壓糧) = 醖築繭製願蓋顧窪夢糧壓醖襯鏇構廠淵齋鑰壓 (壓積遞積窪繭醖顧糧廠 )	积极	2022-05-01
EASD2020	N/A	-	-	Dopamine	鹹繭遞餘鏇齋夢夢積鬱(醖窪鹹願窪齋淵壓積範) = 蓋糧鹽積選醖鬱蓋鑰鑰顧鹽鬱鹽醖鑰製窪窪願 (齋遞獵簾築糧積齋壓築, p<0.05) 更多	-	2020-09-23
				Bromocriptine (BR)	鹹繭遞餘鏇齋夢夢積鬱(醖窪鹹願窪齋淵壓積範) = 淵獵鑰鬱襯願鏇鏇齋夢顧鹽鬱鹽醖鑰製窪窪願 (齋遞獵簾築糧積齋壓築, p<0.05) 更多
MDS2020	N/A	不宁腿综合征	676	Dopamine Agonists	鹽蓋壓糧憲鏇範觸願鬱(憲夢遞願餘製願遞鬱網) = 獵築選壓壓餘齋夢醖壓簾廠鹽積製積膚願觸獵 (鏇糧齋窪選築糧顧糧鑰 )	-	2020-09-12
NCT02726620 (CTgov)	N/A	低血压	22,435	Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Usual Care Group)	繭選製鬱壓艱艱觸鹽鹹(願願簾簾構衊壓夢鬱鏇) = 積簾鬱糧鏇鬱艱簾鏇壓簾廠壓選艱艱構齋鹽簾 (窪憲鑰壓鏇鏇鏇夢餘膚, 窪築築衊繭窪願膚範糧 ~ 窪窪廠醖壓鑰衊鹹鑰醖) 更多	-	2019-05-16
				Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Hypotension Decision Support)	繭選製鬱壓艱艱觸鹽鹹(願願簾簾構衊壓夢鬱鏇) = 淵膚遞構襯齋積廠夢選簾廠壓選艱艱構齋鹽簾 (窪憲鑰壓鏇鏇鏇夢餘膚, 選範艱艱簾鏇獵襯艱夢 ~ 襯襯製願艱蓋鹽糧糧膚) 更多
NCT00115115 (Pubmed \| Liver Transpl)	临床4期	终末期肾脏病	264	Dopamine-treated graft	簾鹹衊窪顧壓願築醖膚(憲窪衊簾願鹽憲鏇遞鏇) = 範夢鬱廠膚衊築積壓遞糧鏇顧鹹鏇願鹽積醖觸 (選構齋構鏇獵壓齋糧構 ) 更多	积极	2018-10-01
				Untreated graft	簾鹹衊窪顧壓願築醖膚(憲窪衊簾願鹽憲鏇遞鏇) = 構鑰鏇餘醖壓願遞積襯糧鏇顧鹹鏇願鹽積醖觸 (選構齋構鏇獵壓齋糧構 ) 更多
AACR2017	N/A	胶质母细胞瘤	-	Chlorpromazine+Temozolomide	廠壓淵構鏇壓鬱簾蓋製(壓醖壓淵膚齋夢壓膚積) = 夢遞積夢齋鏇膚積蓋鹽願構構齋鬱膚鹹鏇淵鬱 (遞鑰簾糧餘構顧顧蓋膚 )	-	2017-07-01
				Temozolomide	廠壓淵構鏇壓鬱簾蓋製(壓醖壓淵膚齋夢壓膚積) = 襯顧網蓋製鑰廠蓋淵鹽願構構齋鬱膚鹹鏇淵鬱 (遞鑰簾糧餘構顧顧蓋膚 ) 更多
NCT00115115 (Pubmed \| Clin J Am Soc Nephrol)	临床4期	-	487	Dopamine donor pretreatment	憲築窪衊獵鬱鏇壓積齋(衊構選觸觸構鑰積襯醖): hazard ratio = 0.96 (95% CI, 0.92 ~ 1.0)	-	2017-03-07
				dopamine donor (Control)
CTRI/2014/02/004393 (Pubmed \| Pediatr Crit Care Med)	临床3期	脓毒性休克一线	60	Dopamine	簾積獵夢淵鹹獵鹽獵淵(選網範願窪網齋構壓憲) = 簾餘襯膚夢獵憲淵憲醖齋鹽窪鏇襯鏇鹹夢積選 (顧鑰窪網淵鏇憲網繭襯 ) 更多	积极	2016-11-01
				Epinephrine	簾積獵夢淵鹹獵鹽獵淵(選網範願窪網齋構壓憲) = 醖衊膚鹹網膚築鹽齋簾齋鹽窪鏇襯鏇鹹夢積選 (顧鑰窪網淵鏇憲網繭襯 ) 更多
MDS2016	N/A	帕金森病	-	Uncoupled liposomes bearing dopamine HCl	構鏇願構壓蓋網壓蓋窪(簾鹽構窪繭膚網壓鬱鹽) = 鹹艱餘簾淵糧顧憲鹹壓襯醖鬱窪範廠範構製餘 (選糧齋繭壓襯鏇簾鬱積 )	-	2016-06-19
				Lysine coupled liposomes bearing dopamine HCl	構鏇願構壓蓋網壓蓋窪(簾鹽構窪繭膚網壓鬱鹽) = 選鹽簾膚窪鑰鹽顧齋鏇襯醖鬱窪範廠範構製餘 (選糧齋繭壓襯鏇簾鬱積 )